BMY vs LNTH: fair value comparison
Bristol-Myers Squibb Company and Lantheus Holdings, Inc. · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, BMY currently sits closer to the top of our discount ranking. LNTH carries the stronger quality grade. LNTH carries the stronger momentum grade.
| BMY | LNTH | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $66.58 | $101.19 |
| 12-month range | $46.02–$65.47 | $51.63–$108.96 |
| Sector rank | #101 of 113 Healthcare | #102 of 113 Healthcare |
| Quality grade | C | A |
| Momentum grade | B | A |
| Leverage | High | Moderate |
| Margin trend | Expanding | Contracting |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Undervalued | Fairly Valued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BMY fair value analysis · LNTH fair value analysis